Rune Raudeberg

Dr. Rune Raudeberg

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in Applied Neuropsychology: Adult
Verified
Journal Article
Open access
JEJens Egeland
Jens Egeland
OLOlaf Lund
Olaf Lund
RRRune Raudeberg
Rune Raudeberg
The Digit Span test has been part of the Wechsler tests from the first version. In the WAIS-IV the Digit Span Sequencing subtest (DSS) was introduced and in the forthcoming WAIS-5 working memory span will also be measured in the visual modality. The present study analyzes WAIS-IV Digit Span, Letter- Number Span (LNS) and WMS-III Spatial Span (SS) performance in a mixed clinical sample, expecting to find that Digit Span Forwards (DSF) lacks sensitivity to the Working Memory impairment evident in D-KEFS Trail Making Test-4 (TMT-4) scores ≤1 SD below normative means in the sample. The results showed DSF score above normative means, Digit Span Backwards (DSB) around mean, while SS and LNS was slightly impaired and DSS impaired at the same level as TMT- 4. A double dissociation was observed in DSF and SS performance between subjects with Language- and Non-verbal learning disorders. Most subjects scored in the average range on the LNS-span and high kurtosis reduced sensitivity. Taking LNS and TMT-4 as criterion measures of WM, regression analyses showed no unique contribution of DSF to the variance in these tests. The study supports prior critiques regarding the composite Digit Span measure and demonstrates that the DSS are more effective than the current version of LNS in identifying reduced Working Memory capacity.

1 February 2021 in The Clinical Neuropsychologist
Verified
Journal Article
Open access
RRRune Raudeberg
Rune Raudeberg
JKJustin E. Karr
Justin E. Karr
GIGrant L Iverson
Grant L Iverson
ÅHÅsa Hammar
Åsa Hammar
Objective: We examined the frequency of possible invalid test scores on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in patients with schizophrenia spectrum disorders, and whether there was an association between scores on the embedded RBANS performance validity tests (PVTs) and self-reported symptoms of apathy as measured by the Initiate Scale of the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A). Methods: Participants included 250 patients (M = 24.4 years-old, SD = 5.7) with schizophrenia spectrum disorders. Base rates of RBANS Effort Index (EI), Effort Scale (ES), and Performance Validity Index (PVI) test scores were computed. Spearman correlations were used to examine the associations between the RBANS PVTs, the RBANS Index scores, and the BRIEF-A Initiate Scale. Regression analyses were used to investigate how well the RBANS PVTs predicted scores on the BRIEF-A Initiate Scale. Results: The frequency of invalid scores on the EI (>3) and the PVI (<42) in participants with schizophrenia spectrum disorders was 6%. The frequency of invalid ES scores (<12) was 28% in the patients compared to 15% in the U.S. standardization sample. There was a small significant correlation between the EI and the BRIEF-A Initiate Scale (rho=.158, p<.05). Conclusions: The rates of invalid scores were similar to previously published studies. Invalid scores on the BRIEF-A were uncommon. Apathy measured with the BRIEF-A Initiate Scale was not associated with performance on the RBANS validity measures or with measures of cognition.

31 October 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ARAne Gretesdatter Rogne
Ane Gretesdatter Rogne
EMEbba Gløersen Müller
Ebba Gløersen Müller
EUEirin Udnæs
Eirin Udnæs
SSSolrun Sigurdardottir
Solrun Sigurdardottir
RRRune Raudeberg
Rune Raudeberg
DDDaniel Dahlberg
Daniel Dahlberg

8 April 2019 in The Clinical Neuropsychologist
Verified
Journal Article
Closed access
RRRune Raudeberg
Rune Raudeberg
GIGrant L Iverson
Grant L Iverson
ÅHÅsa Hammar
Åsa Hammar
Objective: To illustrate and quantify how using different normative systems influences the accuracy of identifying cognitive impairment in people with schizophrenia spectrum disorders. Participants and methods: A convenience sample of 315 patients between 18 and 38 years of age referred for neuropsychological assessment at a psychiatric inpatient hospital in Bergen, Norway, was included. All completed the Norwegian version of the Repeatable Battery for the Assessment of Neuropsy-chological Status (RBANS). Results: There were statistically significant differences between the Immediate Memory, Visuospatial/Constructional, Language, Delayed Memory, and Total Scale Index scores when comparing the U.S. normative scores with the Scandinavian normative scores. The effect sizes were medium. The patient samples scored higher when using the U.S. normative data, suggesting less cognitive impairment. Conclusions: United States normative data yielded less impaired scores for Norwegians with schizophrenia spectrum disorders. The implications of using U.S. versus Scandinavian normative data are discussed.

14 December 2019 in Applied Neuropsychology: Adult
Verified
Journal Article
Open access
RRRune Raudeberg
Rune Raudeberg
GIGrant L Iverson
Grant L Iverson
ÅHÅsa Hammar
Åsa Hammar
Objective: To create clinical normative data tables for Norwegian patients with schizophrenia spectrum disorders, to examine whether clinical normative data from Norway differs from similar normative data from Canada and the U.S., and to illustrate the usefulness of such data. Method: A nationally representative sample of 335 patients from psychiatric hospitals in Bergen, Norway was included. Inclusion criteria were 18–39 years of age, Norwegian as first language, and symptoms of schizophrenia, psychosis, or hallucinations. Comorbid substance abuse was recorded in 134 (40.0%). All completed the Norwegian version of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results: The average scores of patients with schizophrenia spectrum disorders were approximately one to two standard deviations below the mean for healthy adults. There were no significant differences in scores between patients with or without comorbid substance abuse. Men had higher scores than women. Clinical normative reference value look-up tables were created. Conclusions: Clinical normative values were very similar to values from Canada and the U.S. Clinical normative data, as a supplement to standard healthy normative data, can be used to describe patients’ cognitive performance in terms of expectation for their peer group which can be useful for multidisciplinary treatment planning.

10 March 2025 in Substance Abuse Treatment, Prevention, and Policy
Verified
Journal Article
Open access
PDF file
KHKristoffer Høiland
Kristoffer Høiland
RRRune Raudeberg
Rune Raudeberg
JEJens Egeland
Jens Egeland
Cognitive deficits are prevalent among substance use disorder (SUD) patients and affect treatment retention and outcome. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a well-researched instrument in diverse patient groups and has the potential to serve as an effective and accurate method for identifying cognitive impairment in SUD patients. This systematic review examines the RBANS’ ability to detect cognitive impairment in SUD patients. Limitations of knowledge and the need for further research are discussed. We conducted a systematic search using PsycINFO, Medline, and Cochrane databases to identify relevant studies and articles on applying RBANS in SUD. No time limits were imposed on the search. Search words were RBANS, substance use disorder, drug use disorder, and alcohol use disorder, and the most common specific types of drugs (e.g., opiates, cannabis, and methamphetamine). A systematic search identified 232 articles, of which 17 were found eligible and included in the review. Most studies examined patient groups using either alcohol, methamphetamine, or opioids. The results are presented in the form of a narrative review. We identified some evidence that the RBANS can detect group differences between SUD patients and healthy controls, but the findings were somewhat inconsistent. The literature search revealed little information about cognitive profiles, reliability, factor structure, and construct and criterion validity. The evidence concerning the validity and usefulness of the RBANS in SUD populations is scarce. Future research should investigate cognitive profiles, reliability, factor structure, and construct and criterion validity.